3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
6
Terminated
1
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Carcinoma, Hepatocellular
8
Carcinoma, Non-Small-Cell Lung
4
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Liver Neoplasms
3
Stomach Neoplasms
2
Lung Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma, Squamous Cell
2
Urothelial Cancer
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Unresectable Hepatocellular Carcinoma
1
Solid Malignancies
1
Seminoma
1
Prostatic Neoplasms
1
Peritoneal Neoplasms
1
Ovarian Neoplasms
1
Nonseminomatous germ cell tumor
1
Non Small Cell Lung Cancer NSCLC
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Neoplasm Metastasis
1
Microsatellite Instability
1
Metastatic Malignant Female Reproductive System Neoplasm
1
Mesothelioma, Malignant
1
Lung Cancer Metastatic
1
Immunotherapy
1
Hydronephrosis
1
Interventions
balstilimab
2
tremelimumab
1
spartalizumab
1
pembrolizumab
1
lenvatinib
1
Standard of Care
1
Pemetrexed
1
Nivolumab
1
Ipilimumab
1
Carboplatin
1
Axitinib
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Diabetes Mellitus, Insulin-Dependent, 12
×
tremelimumab
×
Clear all
NCT01843374
2026-03-05
Tremelimumab
MedImmune LLC
Phase 2
Active not recruiting
571 enrolled
19 charts